

Curis develops Erivedge, a capsule manufactured for the treatment of adults with skin cancer. Among its major competitors, Curis is ranked in 9th place for NPS while Genentech is 1st, and Pfizer is 2nd.Their current market cap is $1.08B
Curis has a 3.0/5 stars for its overall company culture rated by their employees
